Insulin Glargine (HOE901 - U300)

DRUG2 trials

Sponsors

Sanofi, Yanbing Li

Conditions

Type 2 DiabetesType 2 Diabetes Mellitus

Phase 3

Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications

CompletedNCT02320721

SanofiType 2 Diabetes Mellitus

Start: 2015-01-31End: 2016-05-31Updated: 2020-04-21

Phase 4

Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes

Not yet recruitingNCT07173712

Yanbing LiType 2 Diabetes

Start: 2026-03-15End: 2027-12-31Target: 324Updated: 2026-02-06